Artal Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Artal Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-360,000	Closed	-$5.4M	–	115
2019 Q2	$5.4M	Sell	360,000 -40,000	-10%	-$698K	0.22%	75
2019 Q1	$7.02M	Hold	400,000	–	–	0.29%	64
2018 Q4	$5.93M	Hold	400,000	–	–	0.22%	64
2018 Q3	$9.85M	Hold	400,000	–	–	0.26%	56
2018 Q2	$7.85M	Buy	400,000 +150,000	+60%	+$2.84M	0.17%	53
2018 Q1	$4.69M	Buy	+250,000	New	+$4.08M	0.06%	72

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group's RCKT Position: Q3 2019 in Review

Artal Group sold out of Rocket Pharmaceuticals (RCKT) in Q3 2019, closing a stake of 360,000 shares — an estimated $5.4M sold.

Artal Group first reported a position in RCKT in Q1 2018 and held it in 6 quarters. The position peaked at $9.85M in Q3 2018. 92 funds tracked by Wall St. Rank hold RCKT as of Q3 2019.

Artal Group reported no remaining Rocket Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Artal Group sold 360,000 Rocket Pharmaceuticals shares in Q3 2019, an estimated $5.4M.
Artal Group first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Artal Group's Rocket Pharmaceuticals position peaked at $9.85M in Q3 2018.
92 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2019.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.